Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has required rapid action to control its spread and vaccines are a fundamental solution to this pandemic. The development of rapid and reliable serological tests to monitor the antibody response to coronavirus disease v...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/4/487 |
| _version_ | 1797409101065486336 |
|---|---|
| author | Mohammad Said Ashenagar Akiko Matsumoto Hironori Sakai Mikiko Tokiya Megumi Hara Yoshio Hirota |
| author_facet | Mohammad Said Ashenagar Akiko Matsumoto Hironori Sakai Mikiko Tokiya Megumi Hara Yoshio Hirota |
| author_sort | Mohammad Said Ashenagar |
| collection | DOAJ |
| description | The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has required rapid action to control its spread and vaccines are a fundamental solution to this pandemic. The development of rapid and reliable serological tests to monitor the antibody response to coronavirus disease vaccines is necessary for post-vaccination immune responses. Therefore, in this study, anti-SARS-CoV-2 antibody titers after the first and second doses were monitored using two different measurement systems, a highly sensitive analytical platform of chemiluminescent enzyme immunoassay (CLEIA) and an enzyme-linked immunosorbent assay (ELISA). Our study included 121 participants who received two doses of the BNT162b2 vaccine. Both methods show significant increase in anti-spike protein IgG antibody levels one week after the first vaccination, and then reached at a plateau at week five (week two after the second dose), with a 3.8 × 10<sup>3</sup>-fold rise in CLEIA and a 22-fold rise in ELISA. CLEIA and ELISA showed a good correlation in the high titer range, >10 binding antibody unit (BAU)/mL. Both methods detected higher IgG antibody levels in females compared with male participants after the second vaccination, while CLEIA exhibits the sex difference after the first dose. Thus, our study showed better performance of CLEIA over ELISA in sensitivity, especially in the low concentration range, however ELISA was also useful in the high titer range (>10 BAU/mL) corresponding to the level seen several weeks after the first vaccination. |
| first_indexed | 2024-03-09T04:09:27Z |
| format | Article |
| id | doaj.art-30f79a8d95d04695812578cb2448ffec |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T04:09:27Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-30f79a8d95d04695812578cb2448ffec2023-12-03T14:02:31ZengMDPI AGVaccines2076-393X2022-03-0110448710.3390/vaccines10040487Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA VaccineMohammad Said Ashenagar0Akiko Matsumoto1Hironori Sakai2Mikiko Tokiya3Megumi Hara4Yoshio Hirota5Department of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, JapanDepartment of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, JapanCellspect Co., Ltd., 2-4-23 Kitaiioka, Morioka 020-0857, JapanDepartment of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, JapanDepartment of Preventive Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, JapanClinical Epidemiology Research Center, Medical Co., LTA(SOUSEIKAI), Higashi-ku, Fukuoka 813-0017, JapanThe global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has required rapid action to control its spread and vaccines are a fundamental solution to this pandemic. The development of rapid and reliable serological tests to monitor the antibody response to coronavirus disease vaccines is necessary for post-vaccination immune responses. Therefore, in this study, anti-SARS-CoV-2 antibody titers after the first and second doses were monitored using two different measurement systems, a highly sensitive analytical platform of chemiluminescent enzyme immunoassay (CLEIA) and an enzyme-linked immunosorbent assay (ELISA). Our study included 121 participants who received two doses of the BNT162b2 vaccine. Both methods show significant increase in anti-spike protein IgG antibody levels one week after the first vaccination, and then reached at a plateau at week five (week two after the second dose), with a 3.8 × 10<sup>3</sup>-fold rise in CLEIA and a 22-fold rise in ELISA. CLEIA and ELISA showed a good correlation in the high titer range, >10 binding antibody unit (BAU)/mL. Both methods detected higher IgG antibody levels in females compared with male participants after the second vaccination, while CLEIA exhibits the sex difference after the first dose. Thus, our study showed better performance of CLEIA over ELISA in sensitivity, especially in the low concentration range, however ELISA was also useful in the high titer range (>10 BAU/mL) corresponding to the level seen several weeks after the first vaccination.https://www.mdpi.com/2076-393X/10/4/487antibodyCOVID-19SARS-CoV-2immunoassay testsvaccination |
| spellingShingle | Mohammad Said Ashenagar Akiko Matsumoto Hironori Sakai Mikiko Tokiya Megumi Hara Yoshio Hirota Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine Vaccines antibody COVID-19 SARS-CoV-2 immunoassay tests vaccination |
| title | Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine |
| title_full | Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine |
| title_fullStr | Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine |
| title_full_unstemmed | Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine |
| title_short | Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine |
| title_sort | comparison of cleia and elisa for sars cov 2 virus antibodies after first and second dose vaccinations with the bnt162b2 mrna vaccine |
| topic | antibody COVID-19 SARS-CoV-2 immunoassay tests vaccination |
| url | https://www.mdpi.com/2076-393X/10/4/487 |
| work_keys_str_mv | AT mohammadsaidashenagar comparisonofcleiaandelisaforsarscov2virusantibodiesafterfirstandseconddosevaccinationswiththebnt162b2mrnavaccine AT akikomatsumoto comparisonofcleiaandelisaforsarscov2virusantibodiesafterfirstandseconddosevaccinationswiththebnt162b2mrnavaccine AT hironorisakai comparisonofcleiaandelisaforsarscov2virusantibodiesafterfirstandseconddosevaccinationswiththebnt162b2mrnavaccine AT mikikotokiya comparisonofcleiaandelisaforsarscov2virusantibodiesafterfirstandseconddosevaccinationswiththebnt162b2mrnavaccine AT megumihara comparisonofcleiaandelisaforsarscov2virusantibodiesafterfirstandseconddosevaccinationswiththebnt162b2mrnavaccine AT yoshiohirota comparisonofcleiaandelisaforsarscov2virusantibodiesafterfirstandseconddosevaccinationswiththebnt162b2mrnavaccine |